Chemotherapy's hidden heart toll: study probes lasting damage in breast cancer survivors

NCT ID NCT07680855

Completed Knowledge-focused Sponsor: University of Chile Source: ClinicalTrials.gov ↗

First seen Jul 02, 2026 · Last updated Jul 02, 2026

Summary

This observational study looks at how anthracycline chemotherapy affects inflammation, oxidative stress, and heart function in adult women who had breast cancer. Researchers measure blood markers and use echocardiograms to assess heart changes about 10 years after treatment. The goal is to understand long-term heart risks in survivors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: anthracycline chemotherapy
What this could lead to: If successful, this study could help identify early markers of heart damage in breast cancer survivors, potentially guiding future monitoring and prevention strategies.
What could go wrong: This is a small observational study with only 17 participants and no comparison group, so findings may not apply broadly. It aims to observe long-term effects, not test a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANTHRACYCLINE RELATED CARDIOTOXICITY IN BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm cardiomyopathy due to anthracyclines Cardiotoxicity

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANTHRACYCLINE RELATED CARDIOTOXICITY IN BREAST CANCER BREAST CANCER CARDIOTOXICITY

More trials for these conditions

Other studies related to the condition(s) this trial covers.